Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 25/100

ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Key Takeaway: Rosen Law Firm is investigating potential securities claims on behalf of shareholders of ADMA Biologics, following allegations of misleading business information. The stock experienced a significant decline of 16.6% after a short seller report accused the company of inflating revenue growth through channel stuffing. Shareholders who suffered losses may be eligible for compensation through a class action, with no out-of-pocket expenses. Investors are advised to choose experienced legal counsel for their claims.

Market Sentiment Analysis

CONCERNS & RISKS

  • There are allegations of ADMA Biologics issuing materially misleading business information.
  • The company's stock price fell 16.6% following a report on possible channel stuffing to inflate revenue.
  • A class action is being prepared due to potential losses suffered by shareholders.

Full Press Release Details

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) --
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics, Inc. may have issued materially misleading business information to the investing public.
SO WHAT: If you purchased ADMA Biologics, Inc. securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=57940 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.
WHAT IS THIS ABOUT: On March 24, 2026, Investing.com published an article entitled “ADMA Biologics shares plunge on short seller allegations.” The article stated that ADMA Biologics shares fell “after short seller Culper Research released a report alleging the company engaged in channel stuffing to inflate revenue growth.”
On this news, ADMA Biologics stock fell 16.6% on March 24, 2026.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
Toll Free: (866) 767-3653

Tags

Frequently Asked Questions

What is Rosen Law Firm investigating about ADMA Biologics?

Rosen Law Firm is investigating potential securities claims for shareholders of ADMA Biologics due to allegations of misleading business information.

How can I join the class action against ADMA Biologics?

To join the class action, visit https://rosenlegal.com/submit-form/?case_id=57940 or contact Phillip Kim, Esq. at 866-767-3653.

What caused ADMA Biologics stock to drop significantly?

ADMA Biologics stock fell 16.6% after a short seller's report alleged the company used channel stuffing to inflate revenues.

What makes Rosen Law Firm qualified for this case?

Rosen Law Firm has a strong track record in securities class actions and has recovered hundreds of millions for investors.

Are there any fees to join the class action?

Shareholders may be entitled to compensation without upfront fees through a contingency arrangement.

Last updated: Apr 27, 2026